Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Share-based Compensation: 2013-2025

Historic Share-based Compensation for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $4.6 million.

  • Theravance Biopharma's Share-based Compensation fell 7.80% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.8 million, marking a year-over-year decrease of 7.34%. This contributed to the annual value of $21.4 million for FY2024, which is 15.68% down from last year.
  • As of Q3 2025, Theravance Biopharma's Share-based Compensation stood at $4.6 million, which was up 0.73% from $4.5 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Share-based Compensation peaked at $16.9 million during Q4 2021, and registered a low of $4.5 million during Q2 2025.
  • In the last 3 years, Theravance Biopharma's Share-based Compensation had a median value of $5.4 million in 2024 and averaged $5.5 million.
  • In the last 5 years, Theravance Biopharma's Share-based Compensation rose by 8.79% in 2021 and then crashed by 58.92% in 2022.
  • Over the past 5 years, Theravance Biopharma's Share-based Compensation (Quarterly) stood at $16.9 million in 2021, then tumbled by 58.92% to $7.0 million in 2022, then declined by 16.20% to $5.8 million in 2023, then rose by 0.03% to $5.8 million in 2024, then decreased by 7.80% to $4.6 million in 2025.
  • Its Share-based Compensation stands at $4.6 million for Q3 2025, versus $4.5 million for Q2 2025 and $4.9 million for Q1 2025.